Clinical trials: Optic Neuritis, open to volunteers
B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
This study is a multicenter, prospective cohort study designed to enroll 50 NMOSD patients who receive Satralizumab treatment during the early phase of an NMOSD attack.
- Trial name
- SATURN (NCT07762872)
- Testing
- Satralizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Junwei Hao, MD
Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation).
- Trial name
- PET-AON (NCT06453694)
- Testing
- Efgartigimod Alfa
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Anastasia Vishnevetsky, MD, MPH
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
- Trial name
- NCT07341828
- Testing
- CD20/BCMA-directed CAR-T cells
- Volunteers
- 15 people
- Sponsor
- Huashan Hospital
Optic Neuritis
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
- Trial name
- PIONEER-1 (NCT07623668)
- Testing
- Privosegtor, Methylprednisolone
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Oculis
Neuromyelitis Optica Spectrum Disorders
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients.
- Trial name
- NCT06697535
- Testing
- JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Neuromyelitis Optica Spectrum Disorders, MOGAD
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in…
- Conditions
- Neuromyelitis Optica Spectrum Disorders, MOGAD, Multiple Sclerosis
- Trial name
- PoGe (NCT06865274)
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NMO Spectrum Disorder
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD)…
- Trial name
- NCT07377305
- Testing
- 10Hz tTIS (2-4mA) Intervention
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tang-Du Hospital
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of…
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
- Trial name
- NCT06312644
- Testing
- Ultomiris
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica Spectrum Disorder
Ofatumumab in AQP4-IgG Seropositive NMOSD
This is an open-label, single-arm, multicentre prospective pilot study to assess the efficacy and safety of ofatumumab in patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) in China.
- Trial name
- NCT05504694
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Study Title: A National, Multicenter, Randomized Controlled Trial of the Modified Zipper Therapy in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (ELITE Study) Brief Summary: The goal of this clinical trial is to…
- Trial name
- ELITE (NCT07420296)
- Testing
- Eculizumab administration, High-dose corticosteroid pulse therapy, Plasma exchange (PE)
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tianjin Medical University General Hospital
Optic Neuritis, Multiple Sclerosis
Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool
The goal of this observational study is to determine whether genetic information, together with clinical information, can be used to improve prediction of future multiple sclerosis (MS) diagnosis after a first-time episode of…
- Conditions
- Optic Neuritis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders
- Trial name
- MS Predictor (NCT07704294)
- Testing
- No Intervention: Observational Cohort
- Where
- 3 sites in United Kingdom
- Volunteers
- 180 people
- Sponsor
- King's College London
Neuromyelitis Optica
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
This is an observational study to: evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period prior to exposure), enhance knowledge regarding conventional MRI outcomes…
- Trial name
- AMAZE (NCT06398158)
- Testing
- Ravulizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation.
- Trial name
- ONSTIM (NCT06389968)
- Testing
- Light stimulation
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Neuromyelitis Optica Spectrum Disorders
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
- Trial name
- NCT06413654
- Testing
- B001
- Where
- 51 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen receptor (CAR)-targeted B-cell activating factor…
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder, Myasthenia Gravis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07022197
- Testing
- BAFF-R CART
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Tianjin Medical University General Hospital
Optic Neuritis, Myelitis
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
The purpose of this research is to evaluate if early vs rescue Therapeutic Plasma Exchange (PLEX) treatment algorithm leads to better visual outcomes in severe Optic Neuritis and leads to better neurological disability outcomes…
- Conditions
- Optic Neuritis, Myelitis, Myelitis, Transverse
- Trial name
- TIMELY-PLEX (NCT07100990)
- Testing
- High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
- Where
- 35 sites in United States
- Volunteers
- 382 people
- Sponsor
- Mayo Clinic
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men.
- Trial name
- NCT03401879
- Testing
- Dynamic Vessel Analyzer (DVA), Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Optical coherence tomography (OCT)
- Where
- Austria
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Neuromyelitis Optica
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life.
- Trial name
- OPTIS (NCT05566769)
- Testing
- NMOSDCopilot smartphone application
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 103 people
- Sponsor
- Ad scientiam